Medical Economics November 10, 2023
Richard Payerchin

Finance Committee approved wide-ranging legislation this week.

Senate proposals could have good effects on accountable care organizations (ACOs) and pharmacy benefit managers (PBMs), or possibly major pharmaceutical makers, depending on various analyses by health care industry groups.

The National Association of ACOs (NAACOS) and PBM trade associations Transparency-Rx and Pharmaceutical Care Management Association (PCMA) issued statements responding to various elements in the pending legislation titled “The Better Mental Health Care, Lower-Cost Drugs, and Extenders Act.” On Nov. 8, 2023, the Senate Finance Committee voted 26-0 to send the bill for consideration by the full chamber.

ACO incentives

NAACOS President and CEO Clif Gaus, ScD, praised Committee Chair Sen. Ron Wyden (D-Oregon), who was among the legislators commenting on incentives for...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: ACO (Accountable Care), Congress / White House, Govt Agencies, Payment Models, Pharma, Pharma / Biotech, Provider, Value Based
Related Articles:
HCA Leadership Taking Wait and See Approach to Trump Administration Policies
RFK Jr.'s health tech fix
RFK Jr: Cleveland Clinic Has Developed an AI Nurse; The Clinic: Uh, Not True (Video)
Confirming RFK Jr. Could Mean Swift And Unchecked Upheaval For Vaccines
Some Bipartisan Concurrence on Health Care Issues in the U.S. – But Trust in Health Care Isn’t Bipartisan – KFF’s January 2025 Polls

Share This Article